On 17th October 2014 ,The University of Oxford and Shaanxi Momentum Pharmaceutical Co. Ltd signed a research agreement to study the electrophysiological properties of Xin Su Ning, an antiarrhythmic multi-herbal medicine produced and marketed in China by Shaanxi Momentum Pharmaceutical Co. Ltd. This is the first agreement of this kind, which the University of Oxford had signed with a China private Chinese medicine pharmaceutical. This research project will help Chinese medicine’s development in research that would lead to better understandings of the mechanism of its clinical efficacy in wider public and medical professions internationally, hence to make better contributions to the health care of mankind.

Professor Richard Vaughan-Jones, the President of the British Physiology Society and the Joint Director, Burdon Sanderson Cardiac Science Centre, Department of Physiology, Anatomy and Genetics, University of Oxford, will act as an academic advisor for the project; Professor Peter Robbins, the head of the Department of Physiology, Anatomy and Genetics, and Dr Robert Wilkins and Professor Clive Ellory will give overall support of the project. Dr Yu-ling Ma, Department of Physiology, Anatomy and Genetics, University of Oxford, the project leader said that the company is preparing a 5 year plan of research collaboration with the University of Oxford.

Professor Richard Vaughan-Jones said that the emergence of systems biology helps the development of the study of Chinese medicine; the University of Oxford was one of the early initiators in the study of systems biology. With much interest he is looking forward to seeing the development of the collaborative research project with Shaanxi Momentum Pharmaceutical.